List of nationally authorised medicinal products

Similar documents
List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

Member State Marketing Authorisation Holder (Invented) Strength Pharmaceutical form Route of administration. Novartis Pharma NV

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

WCPT COUNTRY PROFILE December 2017 HUNGARY

WCPT COUNTRY PROFILE December 2017 SWEDEN

WCPT COUNTRY PROFILE December 2017 SERBIA

Smokefree Policies in Europe: Are we there yet?

Cross Border Genetic Testing for Rare Diseases

List of nationally authorised medicinal products

Overview of drug-induced deaths in Europe - What does the data tell us?

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

List of nationally authorised medicinal products

Member State Marketing autorisation Holder Invented Name Strength Pharmaceutical form Route of administration

Current levels and recent trends in health inequalities in the EU: Updates from the EU Report

List of nationally authorised medicinal products

LEBANON. WCPT COUNTRY PROFILE December 2018

DENMARK. WCPT COUNTRY PROFILE December 2018

Please note that this draft Annex I will be updated to amend information on concerned products/mahs

Where we stand in EFORT

GERMANY. WCPT COUNTRY PROFILE December 2018

List of nationally authorised medicinal products

PARALLELISM AND THE LEGITIMACY GAP 1. Appendix A. Country Information

Yersiniosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods. Epidemiology

Drinking guidelines used in the context of early identification and brief interventions in Europe: overview of RARHA survey results

Monthly measles and rubella monitoring report

Engagement in language assessment / Regions of Europe

TEDDY. Teddy Network of Excellence. Annagrazia ALTAVILLA. Ph.D. Sciences Ethics LL.M. Health Law. diterranée

List of nationally authorised medicinal products

List of nationally authorised medicinal products

European Collaboration on Dementia. Luxembourg, 13 December 2006

List of nationally authorised medicinal products

Overview of European Consumption Databases

Where do EU Contries set the limit for low risk drinking.

Marketing Authorisation Holder (Invented) name Strength Pharmaceutical Form Route of administration Novartis Pharma GmbH

REPORT FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS

List of nationally authorised medicinal products

(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use

Trichinellosis SURVEILLANCE REPORT. Annual Epidemiological Report for Key facts. Methods

The health economic landscape of cancer in Europe

List of nationally authorised medicinal products

List of nationally authorised medicinal products

UK bowel cancer care outcomes: A comparison with Europe

Update on public hearing

Media Release. Inaugural study reveals that more than one in four women in European and Central Asian prisons locked up for drug offences

508 the number of suicide deaths in deaths per 100,000 people was the suicide rate in Suicide deaths in 2013 by gender

The cancer burden in the European Union and the European Region: the current situation and a way forward

Rheumatoid Arthritis Disease Burden and Access to Treatment

European Community Pharmacy: a reference in Public Health

Alcohol-related harm in Europe and the WHO policy response

Q1 What age are you?

Real Life, Real PD Survey

Research paper: Legal treatment of the use of cannabis for medical purposes in the member states of the European Union

List of nationally authorised medicinal products

real-time AQ data 2007 and plans for 2008

Manuel Cardoso RARHA Executive Coordinator Public Health MD Senior Advisor Deputy General-Director of SICAD - Portugal

Annex I. Article 107i of Directive 2001/83/EC. Procedure number: EMEA/H/A-107i/ March 2013 EMA/147828/2013 Patient Health Protection

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

List of nationally authorised medicinal products

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Outcome of proficiency test on EIA serology

Biology Report. Is there a relationship between Countries' Human Development Index (HDI) level and the incidence of tuberculosis?

Meeting report, September 2005

Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke

Men & Health Work. Difference can make a difference Steve Boorman & Ian Banks RSPH Academy 2013

Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration

Underage drinking in Europe

The Risk of Alcohol in Europe. Bridging the Gap June 2004

Global Trade in Lightweight Coated Writing Paper TradeData International Pty Ltd ( Page 1 5/18/2015

Transmission, processing and publication of HBS 2015 data

ALCOHOL CONSUMPTION IN EUROPE; TRADITIONS, GENERATIONS, CULTURE AND POLICY

EUROPEAN CITIZENS DIGITAL HEALTH LITERACY

Emerging Risks Mapping of Activities in Member States. 67th Advisory Forum meeting, Utrecht, The Netherlands, 6 February 2018

Table 7.1 Summary information for lung cancer in Ireland,

MEDICINES SHORTAGES PGEU GPUE. John Chave - Secretary general. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

L 322/24 Official Journal of the European Union

SOITC Press Ad FAQs. Q: When will these Terms and Conditions changes come into effect?

We are here for our fellow patients

Estimating Smoking Related Cause of Death: a Cohort Approach Based on Lung Cancer Mortality in six European Countries

Alcohol consumption, alcohol dependence and attributable burden of disease in Europe

Table 6.1 Summary information for colorectal cancer in Ireland,

European Status report on Alcohol and Health

Palliative nursing care of children and young people across Europe

Measles and rubella monitoring January 2015

Department of Biological Standardisation OMCL Network & Healthcare (DBO)

Transcription:

11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill Place Canary Wharf London E14 5EU Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525 Send a question via our website www.ema.europa.eu/contact An agency of the European Union European Medicines Agency, 2016. Reproduction provided the source is acknowledged.

Calcitonin Novartis IE/H/0117/001 & IE/H/0117/002 1-20665 & 1-23961 Novartis Pharma Gmbh Austria Calcitonin Novartis IE/H/0117/003 16880 Novartis Pharma Gmbh Austria Calcitonin Novartis IE/H/0117/004 1-18623 Novartis Pharma Gmbh Austria Calcitonin Sandoz 2126592 26592.00.00 Hexal Ag Germany Calcitonina Hubber 57.064 Meda Pharma S.A.U. Spain Calcitonina Hubber 59486 Meda Pharma S.A.U. Spain Calcitonina Sandoz IE/H/0117/003 023704 202/M Novartis Farma S.P.A. Italy Calcitonina Sandoz IE/H/0117/004 023704 214/M Novartis Farma S.P.A. Italy Sociedade De Produtos Farmaceuticos Calcitonina Wander IE/H/0122/001 2637783 Wander, Lda.* Karil IE/H/0117/003 4104.00.00 Novartis Pharma Gmbh Germany Karil IE/H/0122/001 0135/00/06/0049 Novartis Pharma Gmbh Luxembourg Karil IE/H/0122/001 49029.00.00 Novartis Pharma Gmbh Germany Miacalcic 088/02001 Malta Miacalcic 18426 Cyprus Miacalcic 5363-I-561/10 Novartis Pharma Gmbh Slovenia Miacalcic 5363-I-562/10 Novartis Pharma Gmbh Slovenia Miacalcic 5400/2005/01 Novartis Pharma Gmbh Romania Miacalcic 56/0014/75-S Novartis, S.R.O. Slovakia Miacalcic 56/0014/75-S Novartis, S.R.O. Slovakia Miacalcic 56/014/75-A/C & 56/014/75-B/C Novartis, S.R.O. Czech Republic Miacalcic 56/573/97-C Novartis, S.R.O. Czech Republic Miacalcic BE168524 Novartis Pharma N.V. Belgium Miacalcic BE173031 Novartis Pharma N.V. Belgium Miacalcic OGYI-T-1342/01 Novartis Hungária Kft. Pharma Hungary Miacalcic OGYI-T-1342/02 Novartis Hungária Kft. Pharma Hungary EMA/255959/2016 Page 2/5

Miacalcic OGYI-T-1342/03 & OGYI-T-1342/04 Novartis Hungária Kft. Pharma Hungary Miacalcic PL 00101/0203 Miacalcic R/1193 & R/1194 Novartis Poland Sp. Z O. O. Poland Miacalcic IE/H/0117/001 198430301 & 198430302 Novartis (Hellas) S.A.C.I. Greece Novartis Farma - Produtos Farmacêuticos Miacalcic IE/H/0117/001 3068384 & 8668525 S.A. Miacalcic IE/H/0117/001 61699 Novartis Farmacéutica S.A. Spain Miacalcic IE/H/0117/001 PA 13/40/5 Miacalcic IE/H/0117/001 PL 00101/0586 Miacalcic IE/H/0117/002 PA 13/40/4 Miacalcic IE/H/0117/003 06594 Novartis Healthcare A/S Denmark 198430101 & 198430102 & Miacalcic IE/H/0117/003 198430103 & 198430104 Novartis (Hellas) S.A.C.I. Greece Miacalcic IE/H/0117/003 56198 Novartis Farmacéutica S.A. Spain Miacalcic IE/H/0117/003 / IE/H/117/001 6184 / 95-3370 Novartis Norge As Norway Miacalcic IE/H/0117/003 7325 Novartis Finland Oy Finland Miacalcic IE/H/0117/003 761970 Novartis Healthcare A/S Iceland Miacalcic IE/H/0117/003 9290 Novartis Sverige Ab Sweden Miacalcic IE/H/0117/003 PA 13/40/2 Miacalcic IE/H/0117/003 PL 00101/0095R Miacalcic IE/H/0117/004 3400933020323 & 3400957383251 & 3400957383312 & 3400957383480 Novartis Pharma S.A.S. France Miacalcic IE/H/0117/004 BE126901 Novartis Pharma N.V. Belgium EMA/4301/2016 Page 3/5

Miacalcic IE/H/0117/004 BE126901 Novartis Pharma N.V. Belgium Miacalcic IE/H/0117/004 PA 13/40/1 Miacalcic IE/H/0117/004 PL 00101/0202 Miacalcic / миакалцик 20000833 Novartis Pharma Gmbh Bulgaria Miacalcic Nasal R/7916 Novartis Pharma Gmbh Poland Miacalcic Nasal IE/H/0117/001 15421 Novartis Finland Oy Finland Miacalcic Nasal IE/H/0117/001 15678 Novartis Healthcare A/S Denmark Miacalcic Nasal IE/H/0117/001 IS/1/01/112/01 Novartis Healthcare A/S Iceland Miacalcic Nasal/ миакалцик назал 20000525 Novartis Pharma Gmbh Bulgaria Miakaril IE/H/0122/001 PA 13/94/1 Oseototal IE/H/0122/001 62538 Novartis Farmacéutica S.A. Spain Osseocalcina IE/H/0123/001 3068483 & 8727222 Laboratorio Normal-Produtos Farmaceuticos, Lda Ostulex IE/H/0123/001 PA 13/93/1 Calsyn 340 657-6 & 343 506-9 & 343 507-5 & 343 508-1 Sanofi-Aventis France France Calsyn 340 658-2 & 343 502-3 & 343 504-6 & 343 505-2 Sanofi-Aventis France France Calsynar 50 UI 57246 Sanofi-Aventis SA Spain Calsynar 100 UI 54532 Sanofi-Aventis SA Spain Calsynar 200 UI 59213 Sanofi-Aventis SA Spain Calsynar 200 UI 62183 Sanofi-Aventis SA Spain Calsynar 205810101; 205810102; 205810103; 205810104 Sanofi-Aventis AEBE Greece Calsynar 205810201; 205810202; Sanofi-Aventis AEBE Greece Calsynar 205810401 Sanofi-Aventis AEBE Greece EMA/4301/2016 Page 4/5

Calcitar 200 4470985 Sanofi-aventis Produtos Farmaceuticos S.A. Calcyn 200 4471082 Sanofi-aventis Produtos Farmaceuticos S.A. Ospor IE/H/0123/001 62540 Laboratorios Padró, S.A. Spain EMA/4301/2016 Page 5/5